Skip to main content
Nanjing Well Pharmaceutical Group Co.,Ltd. logo

Nanjing Well Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603351 ISIN · CNE100003JD4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2026-05-19 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 603351

About Nanjing Well Pharmaceutical Group Co.,Ltd.

http://en.well-js.com/

Nanjing Well Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of pharmaceutical excipients and synthetic lubricants. The company provides a comprehensive range of high-purity chemical products, including polyethylene glycols, polysorbates, sorbitan esters, and poloxamers, which are essential for drug formulation and delivery systems. Beyond the pharmaceutical sector, its portfolio serves the personal care, food processing, and industrial lubricant markets. The group operates advanced manufacturing facilities compliant with Good Manufacturing Practice (GMP) standards, focusing on quality control and technical innovation. By leveraging its R&D capabilities, the company develops customized solutions to meet specific formulation requirements, maintaining a significant presence as a supplier of specialty chemical ingredients for health and industrial applications.

Recent filings

Filing Released Lang Actions
威尔药业第四届董事会第一次会议决议公告
Board/Management Information Classification · 92% confidence The document is a formal announcement of the resolutions passed at the company’s fourth board meeting, including election of the board chairman, formation of board committees, and appointments of senior management and the securities affairs representative. It does not contain financial statements or investor presentation material; rather, it details board and executive appointments. This matches the definition for Board/Management Information (MANG).
2026-05-19 Chinese
威尔药业2025年年度股东会会议资料
AGM Information Classification · 95% confidence The document is titled “2025年年度股东会会议资料” (“2025 Annual General Meeting Meeting Materials”) and consists of the AGM’s notice, agenda, proposals (board report, profit distribution, auditor appointment, credit application, charter amendment, director elections, etc.), and supporting materials including the independent directors’ report. It is clearly the set of materials provided for an annual shareholders’ meeting rather than the formal yearly financial report (10-K), earnings release, or voting results. Therefore, it should be classified as AGM Information (AGM-R).
2026-05-13 Chinese
威尔药业关于2025年度暨2026年第一季度业绩说明会召开情况的公告
Regulatory Filings Classification · 80% confidence The document is an official SSE regulatory announcement (“公告”) summarizing the 2025 annual and 2026 Q1 performance briefing meeting and Q&A with investors. It does not contain full financial statements (so it’s not an Interim Report) nor is it a standalone investor slide deck (Investor Presentation). It’s a routine regulatory filing disclosing meeting details and investor Q&A, fitting the general “Regulatory Filings” category as a fallback for miscellaneous compliance announcements.
2026-05-13 Chinese
威尔药业关于召开2025年度暨2026年第一季度业绩说明会的公告
Regulatory Filings Classification · 85% confidence The document is a formal notice (“公告”) from a Chinese issuer announcing the timing, format, and logistics of an upcoming performance briefing (业绩说明会) for the company’s 2025 annual and 2026 Q1 results. It is not the presentation or slides themselves, nor an earnings release, transcript, or regulatory filing of financial statements. It simply schedules a webcast/Q&A session, making it a general announcement that doesn’t fit the other specific categories. Under our taxonomy, such notices fall into the fallback category for general regulatory announcements—RNS.
2026-04-27 Chinese
威尔药业2025年度审计委员会对会计师事务所履行监督职责情况报告
Governance Information Classification · 80% confidence The document is the Board Audit Committee’s annual oversight report on the external audit firm’s qualifications, independence and performance. It is not the auditor’s own report (which would be AR) nor a full annual/interim report, but rather a formal governance document describing internal committee procedures and evaluations. Therefore it fits the Governance Information category (CGR).
2026-04-27 Chinese
威尔药业关于增加经营范围及修订《公司章程》的公告
Governance Information Classification · 89% confidence The document is an official corporate announcement by the board of Nanjing Will Pharmaceutical Group Co., Ltd. regarding the approval of amendments to the company’s Articles of Association and the expansion of its business scope. This pertains to internal governance rules and charter revisions, fitting the definition of Governance Information (CGR). It is not a proxy statement, dividend notice, or financial report, but rather a governance amendment announcement.
2026-04-27 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.